RET proto-oncogene mutations in thyroid carcinomas: clinical relevance

Area of Science:

• Oncology
• Genetics
• Endocrinology

Background:

• RET gene mutations are implicated in both papillary and medullary thyroid carcinomas.
• RET/PTC oncogene rearrangements are causative in a significant proportion of papillary thyroid carcinomas.
• Germline and somatic RET point-mutations are crucial in the pathogenesis of hereditary and sporadic medullary thyroid cancer, respectively.

Purpose of the Study:

• To review the clinical implications of RET gene mutations in thyroid cancer patients.
• To highlight the role of RET mutations in papillary and medullary thyroid carcinomas.
• To discuss the impact of genetic screening for hereditary medullary thyroid cancer.

Main Methods:

• Literature review focusing on RET gene mutations in thyroid cancer.
• Analysis of the role of RET/PTC oncogene in papillary thyroid carcinoma.
• Examination of germline and somatic RET point-mutations in medullary thyroid cancer.

Main Results:

• RET/PTC oncogene frequency and type in papillary tumors are influenced by radiation exposure, age, and histology, but mutation presence doesn't affect tumor behavior or treatment response.
• Germline RET point-mutations are found in nearly all hereditary medullary thyroid cancer cases.
• Somatic RET point-mutations are present in about half of sporadic medullary thyroid cancer cases.

Conclusions:

• Genetic screening for RET mutations allows identification of at-risk individuals for hereditary medullary thyroid cancer.
• Early detection and intervention in pre-clinical stages or even pre-disease are possible for mutation carriers.
• Understanding RET mutation's clinical impact is crucial for thyroid cancer patient management and screening strategies.